Emergence of resistant variants of HIV in vivo during monotherapy with the proteinase inhibitor saquinavir

Journal of Antimicrobial Chemotherapy

Volumn 39, Issue 6, 1997, Pages 771-779

  Ives, K J ^a,e   Jacobsen, H ^b   Galpin, S A ^a   Garaev, M M ^c   Dorrell, L ^a   Mous, J ^b   Bragman, K ^d   Weber, J N ^a,e  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c D I IVANOVSKY INSTITUTE OF VIROLOGY   (Russian Federation)

^d IQVIA   (United States)

^e University of Bath   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE; PROTEINASE INHIBITOR; SAQUINAVIR; VIRUS RNA;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONONUCLEAR CELL; PHENOTYPE; PLASMA; POINT MUTATION;

ADULT; ANTI-HIV AGENTS; DNA PRIMERS; DRUG RESISTANCE; GENES, GAG; GENES, POL; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; POLYMERASE CHAIN REACTION; SAQUINAVIR; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 0030789573     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/39.6.771     Document Type: Article

References (27)

1. Larder, B. A., Darby, G. & Richman, D. D. (1989). HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243, 1731-4.
2. Rooke, R., Tremblay, M., Soudeyns, H., DeStephano, L., Yao, X.-J., Fanning, M. et al. (1989). Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy. AIDS 3, 411-5.
3. Rooke, R., Parniak, M. A., Tremblay, M., Soudeyns, H., Li, X. G., Gao, Q. et al. (1991). Biological comparison of wild-type and zidovudine-resistant isolates of human immunodeficiency virus type 1 from the same subjects: susceptibility and resistance to other drugs. Antimicrobial Agents and Chemotherapy 35, 988-91.
4. Richman, D., Shih, C. K., Lowy, I., Rose, J., Prodanovich, P., Goff, S. et al. (1991). Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proceedings of the National Academy of Sciences of the United States of America 88, 11241-5.
5. Larder, B. A. & Kemp, S. D. (1989). Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246, 1155-8.
6. Kellam, P., Boucher, C. A. & Larder, B. A. (1992). Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance of zidovudine. Proceedings of the National Academy of Sciences of the United States of America 89, 1934-8.
7. St Clair, M. H., Martin, J. L., Tudor-Williams, G., Bach, M. C., Vavro, C. L., King, D. M. et al. (1991). Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253, 1557-9.
8. Tisdale, M., Kemp, S. D., Parry, N. R. & Larder, B. A. (1993). Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proceedings of the National Academy of Sciences of the United States of America 90, 5653-6.
9. Roberts, N. A., Martin, J. A., Kinchington, D., Broadhurst, A. V., Craig, J. C., Duncan, I. B. et al. (1990). Rational design of peptide-based HIV proteinase inhibitors. Science 248, 358-61.
10. Craig, J. C., Duncan, I. B., Hockley, D., Grief, C., Roberts, N. A. & Mills, J. S. (1991). Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. Antiviral Research 16, 295-305.
11. Galpin, S., Roberts, N. A., O'Connor, T., Jeffries, D. J. & Kinchington, D. (1994). Antiviral properties of the HIV-1 proteinase inhibitor Ro 31-8959. Antiviral Chemistry and Chemotherapy 5, 43-5.
12. Jacobsen, H., Yasargil, K., Winslow, D. L., Craig, J. C., Kröhn, A., Duncan, I. B. et al. (1995). Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitors Ro 31-8959. Virology 206, 527-34.
13. Craig, J. C., Whittaker, L., Duncan, I. B. & Roberts, N. A. (1993). In vitro resistance to an inhibitor of HIV proteinase (Ro 31-8959) relative to inhibitors of reverse transcriptase (AZT and TIBO). Antiviral Chemistry and Chemotherapy 4, 335-9.
14. Singh, M. K., Toyoshima, T., Markowitz, M., Kempf, D. J., Norbeck, D. W., Erickson, J. et al. (1993). Characterization of viral mutants resistant to a C2-symmetrical inhibitor of HIV-1 protease. Journal of Cellular Biochemistry, Suppl. 17E, 86.
15. Chen, C.-M., Saldivar, A., Turon, M., Wideburg, N. E., Robins, T., Vasavanonda, S. et al. (1994). Biochemical characterization of HIV-1 protease mutants resistant to A-77003, A-80987. Journal of Cellular Biochemistry 18, Suppl. D, 166.
16. el-Farrash, M. A., Kuroda, M. J., Kitazaki, T., Masuda, T., Kato, K., Hatanaka, M. et al. (1994). Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor. Journal of Virology 68, 233-9.
17. 2-symmetric protease inhibitor. Journal of Virology 68, 2016-20.
18. Kempf, D. J., Flentge, C., Marsh, K. C., McDonald, E., Robins, T., Vasavanonda, S. et al. (1994). Symmetry-based inhibitors of HIV protease: oral bioavailability and resistance emergence. Journal of Cellular Biochemistry, Suppl. 18D, 130.
19. Otto, M. J., Garber, S., Winslow, D. L., Reid, C. D., Aldrich, P., Jadhav, P. K. et al. (1993). In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease. Proceedings of the National Academy of Sciences of the United States of America 90, 7543-7.
20. Markowitz, M., Mo, H., Kempf, D. J., Norbeck, D. W., Bhat, T. N., Erickson, J. W. et al. (1995). Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. Journal of Virology 69, 701-6.
21. Kitchen, V. S., Skinner, C., Ariyoshi, K., Lane, E. A., Duncan, I. B., Burckhardt, J. et al. (1995). Safety and activity of saquinavir in HIV infection. Lancet 345, 952-5.
22. Kitchen, V., Stewart, F., Bragman, K. & Weber, J. (1995). Emerging proteinase inhibitors. Lancet 345, 1512.
23. Ariyoshi, K., Bloor, S., Bieniasz, P. D., Bourrelly, M., Foxall, R. & Weber, J. N. (1994). Development of a rapid quantitative assay for HIV-1 plasma infectious viraemia-culture-PCR (CPID). Journal of Medical Virology 43, 28-32.
24. Bobkov, A., Garaev, M. M., Rzhaninova, A., Kaleebu, P., Pitman, R., Weber, J. N. et al. (1994). Molecular epidemiology of HIV-1 in the former Soviet Union: analysis of env V3 sequences and their correlation with epidemiologic data. AIDS 8, 619-24.
25. Saiki, R. K., Scharf, S., Faloona, F., Mullis, K. B., Horn, G. T., Erlich, H. A. et al. (1985). Enzymatic amplification of β-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 230, 1350-4.
26. Lamarre, D., Doyon, I., Croteau, G., Pilote, L. & Thibeault, D. (1995). Molecular basis of HIV-1 resistance to protease inhibitors. Structural flexibility of the protease and second-site compensatory mutations in cleavage sites. In Fourth International Workshop of HIV-1 Drug Resistance, Sardinia, Italy. Abstract 62.
27. Condra, J. H., Schleif, W. A., Blahy, O. M., Gabryelski, L. J., Grahan, D. J., Quintero, J. C. et al. (1995). In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374, 569-71.